In diabetic patients on hemodialysis, glycated albumin (GA) might provide a valuable alternative for predicting mortality, according to a study in Nephrology Dialysis Transplantation.
The study included a cohort of 84,282 diabetic patients on maintenance hemodialysis in Japan, identified from the Japanese Society for Dialysis Therapy Renal Data Registry. Mean age was 67 years and mean time on dialysis 6.4 years; about 70% of patients were male. Measurements of both GA and glycated hemoglobin (HbA1c) were available for 22,441 patients. One-year follow-up data were used to assess the two measures as predictors of mortality, with adjustment for potential